Progesterone Receptor Positive (PR+) breast cancer is a distinct biological subtype of hormone receptor positive breast cancer. This type of cancer grows in response to progesterone, a hormone that is ...

Dual anti–human epidermal growth factor receptor 2 (HER2) therapy plus chemotherapy followed by maintenance treatment with HER2-targeted and endocrine therapies is standard first-line treatment for ...

Faslodex (fulvestrant) is a prescription medicine used for people with certain types of breast cancer. Faslodex is given as an injection into the buttocks (gluteal area) by a health care provider in a ...

A new research perspective was published in Oncotarget's Volume 14 on July 1, 2023, entitled, "Deciphering the mechanisms of action of progesterone in breast cancer." "This research perspective is ...

One of the first clues pathologists look for in tissue from a newly diagnosed breast cancer patient is the estrogen receptor, a nuclear protein that converts hormonal messages in the bloodstream into ...

AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone ...